{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:27:33Z","timestamp":1788852453207,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"publisher","award":["2018-CX-20"],"award-info":[{"award-number":["2018-CX-20"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07827-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:56:07Z","timestamp":1765367767000},"page":"1401-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum urate, cardiovascular mediators, and atrial fibrillation: genetic evidence for URAT1-targeted therapy"],"prefix":"10.1007","volume":"45","author":[{"given":"Chaoyang","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enze","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5928-8043","authenticated-orcid":false,"given":"Enhui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"7827_CR1","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cjca.2019.05.024","volume":"35","author":"P Meyre","year":"2019","unstructured":"Meyre P, Blum S, Berger S et al (2019) Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol 35:1332\u20131343. https:\/\/doi.org\/10.1016\/j.cjca.2019.05.024","journal-title":"Can J Cardiol"},{"key":"7827_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jama.2024.22451","volume":"333","author":"D Ko","year":"2025","unstructured":"Ko D, Chung MK, Evans PT et al (2025) Atrial fibrillation: a review. JAMA 333:329. https:\/\/doi.org\/10.1001\/jama.2024.22451","journal-title":"JAMA"},{"key":"7827_CR3","doi-asserted-by":"publisher","first-page":"1429465","DOI":"10.3389\/fendo.2025.1429465","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Shi L, Qin C et al (2025) Decoding the mystery between hyperuricemia and atrial fibrillation: new causal links through mediating proteomics. Front Endocrinol 16:1429465. https:\/\/doi.org\/10.3389\/fendo.2025.1429465","journal-title":"Front Endocrinol"},{"key":"7827_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.268","volume":"231","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara M, Niwa K, Nishihara S et al (2017) Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol 231:137\u2013142. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.268","journal-title":"Int J Cardiol"},{"key":"7827_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tcm.2018.06.004","volume":"29","author":"G Giannopoulos","year":"2019","unstructured":"Giannopoulos G, Angelidis C, Deftereos S (2019) Gout and arrhythmias: in search for causation beyond association. Trends Cardiovasc Med 29:41\u201347. https:\/\/doi.org\/10.1016\/j.tcm.2018.06.004","journal-title":"Trends Cardiovasc Med"},{"key":"7827_CR6","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/eurheartj\/ehz154","volume":"40","author":"JA Singh","year":"2019","unstructured":"Singh JA, Cleveland JD (2019) Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. Eur Heart J 40:3046\u20133054. https:\/\/doi.org\/10.1093\/eurheartj\/ehz154","journal-title":"Eur Heart J"},{"key":"7827_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/annrheumdis-2015-209008","volume":"76","author":"JA Singh","year":"2017","unstructured":"Singh JA, Yu S (2017) Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data. Ann Rheum Dis 76:72\u201378. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209008","journal-title":"Ann Rheum Dis"},{"key":"7827_CR8","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","volume":"43","author":"W Doehner","year":"2022","unstructured":"Doehner W, Anker SD, Butler J et al (2022) Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J 43:3435\u20133446. https:\/\/doi.org\/10.1093\/eurheartj\/ehac320","journal-title":"Eur Heart J"},{"key":"7827_CR9","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A (2016) Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 27:3253\u20133265. https:\/\/doi.org\/10.1681\/ASN.2016010098","journal-title":"J Am Soc Nephrol"},{"key":"7827_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318:1925\u20131926. https:\/\/doi.org\/10.1001\/jama.2017.17219","journal-title":"JAMA"},{"key":"7827_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a038984","volume":"11","author":"E Sanderson","year":"2021","unstructured":"Sanderson E (2021) Multivariable Mendelian randomization and mediation. Cold Spring Harb Perspect Med 11:a038984. https:\/\/doi.org\/10.1101\/cshperspect.a038984","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7827_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter AR, Sanderson E, Hammerton G et al (2021) Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol 36:465\u2013478. https:\/\/doi.org\/10.1007\/s10654-021-00757-1","journal-title":"Eur J Epidemiol"},{"key":"7827_CR13","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M et al (2020) Genetic drug target validation using Mendelian randomisation. Nat Commun 11:3255. https:\/\/doi.org\/10.1038\/s41467-020-16969-0","journal-title":"Nat Commun"},{"key":"7827_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104543","volume":"90","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang B, Liu Q et al (2023) Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. EBioMedicine 90:104543. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104543","journal-title":"EBioMedicine"},{"key":"7827_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW, Richmond RC, Woolf BAR et al (2021) Strengthening the reporting of observational studies in epidemiology using Mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 375:n2233. https:\/\/doi.org\/10.1136\/bmj.n2233","journal-title":"BMJ"},{"key":"7827_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41588-019-0504-x","volume":"51","author":"A Tin","year":"2019","unstructured":"Tin A, Marten J, Halperin Kuhns VL et al (2019) Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet 51:1459\u20131474. https:\/\/doi.org\/10.1038\/s41588-019-0504-x","journal-title":"Nat Genet"},{"key":"7827_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41588-018-0171-3","volume":"50","author":"JB Nielsen","year":"2018","unstructured":"Nielsen JB, Thorolfsdottir RB, Fritsche LG et al (2018) Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet 50:1234\u20131239. https:\/\/doi.org\/10.1038\/s41588-018-0171-3","journal-title":"Nat Genet"},{"key":"7827_CR18","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10654-024-01138-0","volume":"39","author":"L Wang","year":"2024","unstructured":"Wang L, Mesa-Eguiagaray I, Campbell H et al (2024) A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes. Eur J Epidemiol 39:869\u2013880. https:\/\/doi.org\/10.1007\/s10654-024-01138-0","journal-title":"Eur J Epidemiol"},{"key":"7827_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajhg.2023.12.002","volume":"111","author":"AJ Grant","year":"2024","unstructured":"Grant AJ, Burgess S (2024) A Bayesian approach to mendelian randomization using summary statistics in the univariable and multivariable settings with correlated pleiotropy. Am J Hum Genet 111:165\u2013180. https:\/\/doi.org\/10.1016\/j.ajhg.2023.12.002","journal-title":"Am J Hum Genet"},{"key":"7827_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3390\/genes13091541","volume":"13","author":"B Woolf","year":"2022","unstructured":"Woolf B, Zagkos L, Gill D (2022) TwoStepCisMR: a novel method and R package for attenuating bias in cis-mendelian randomization analyses. Genes 13:1541. https:\/\/doi.org\/10.3390\/genes13091541","journal-title":"Genes"},{"key":"7827_CR21","doi-asserted-by":"publisher","DOI":"10.1515\/ijb-2015-0074","volume":"12","author":"JR Thompson","year":"2016","unstructured":"Thompson JR, Minelli C, Del Greco M F (2016) Mendelian randomization using public data from genetic consortia. Int J Biostat 12:20150074. https:\/\/doi.org\/10.1515\/ijb-2015-0074","journal-title":"Int J Biostat"},{"key":"7827_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41562-019-0566-x","volume":"3","author":"AD Grotzinger","year":"2019","unstructured":"Grotzinger AD, Rhemtulla M, de Vlaming R et al (2019) Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat Hum Behav 3:513\u2013525. https:\/\/doi.org\/10.1038\/s41562-019-0566-x","journal-title":"Nat Hum Behav"},{"key":"7827_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.measurement.2005.01.001","volume":"38","author":"R Willink","year":"2005","unstructured":"Willink R, Lira I (2005) A united interpretation of different uncertainty intervals. Measurement 38:61\u201366. https:\/\/doi.org\/10.1016\/j.measurement.2005.01.001","journal-title":"Measurement"},{"key":"7827_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13300","volume":"50","author":"M Hong","year":"2020","unstructured":"Hong M, Park J, Yang P et al (2020) A mendelian randomization analysis: the causal association between serum uric acid and atrial fibrillation. Eur J Clin Invest 50:e13300. https:\/\/doi.org\/10.1111\/eci.13300","journal-title":"Eur J Clin Invest"},{"key":"7827_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70089","volume":"48","author":"S Yu","year":"2025","unstructured":"Yu S, Wang W, Gao Y et al (2025) Serum urate and atrial fibrillation: a bidirectional Mendelian randomization study. Clin Cardiol 48:e70089. https:\/\/doi.org\/10.1002\/clc.70089","journal-title":"Clin Cardiol"},{"key":"7827_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2013","unstructured":"K\u00f6ttgen A, Albrecht E, Teumer A et al (2013) Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 45:145\u2013154. https:\/\/doi.org\/10.1038\/ng.2500","journal-title":"Nat Genet"},{"key":"7827_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","volume":"8","author":"UAA Sharaf El Din","year":"2017","unstructured":"Sharaf El Din UAA, Salem MM, Abdulazim DO (2017) Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res 8:537\u2013548. https:\/\/doi.org\/10.1016\/j.jare.2016.11.004","journal-title":"J Adv Res"},{"key":"7827_CR28","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.3390\/ijms22179221","volume":"22","author":"H Yanai","year":"2021","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H (2021) Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci 22:9221. https:\/\/doi.org\/10.3390\/ijms22179221","journal-title":"Int J Mol Sci"},{"key":"7827_CR29","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","volume":"79","author":"C Borghi","year":"2022","unstructured":"Borghi C, Agnoletti D, Cicero AFG et al (2022) Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension 79:1927\u20131936. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.17956","journal-title":"Hypertension"},{"key":"7827_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2019.106565","volume":"120","author":"F Cortese","year":"2019","unstructured":"Cortese F, Giordano P, Scicchitano P et al (2019) Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects. Vascul Pharmacol 120:106565. https:\/\/doi.org\/10.1016\/j.vph.2019.106565","journal-title":"Vascul Pharmacol"},{"key":"7827_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","volume":"122","author":"P Verdecchia","year":"2018","unstructured":"Verdecchia P, Angeli F, Reboldi G (2018) Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res 122:352\u2013368. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311402","journal-title":"Circ Res"},{"key":"7827_CR32","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","volume":"26","author":"R Nieuwlaat","year":"2005","unstructured":"Nieuwlaat R, Capucci A, Camm AJ et al (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J 26:2422\u20132434. https:\/\/doi.org\/10.1093\/eurheartj\/ehi505","journal-title":"Eur Heart J"},{"key":"7827_CR33","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1152\/ajpheart.00702.2020","volume":"320","author":"F Liang","year":"2021","unstructured":"Liang F, Wang Y (2021) Coronary heart disease and atrial fibrillation: a vicious cycle. Am J Physiol Heart Circ Physiol 320:H1\u2013H12. https:\/\/doi.org\/10.1152\/ajpheart.00702.2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7827_CR34","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1093\/eurheartj\/ehac257","volume":"43","author":"S Pabel","year":"2022","unstructured":"Pabel S, Sossalla S (2022) Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemma. Eur Heart J 43:3376\u20133378. https:\/\/doi.org\/10.1093\/eurheartj\/ehac257","journal-title":"Eur Heart J"},{"key":"7827_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacl.2019.12.002","volume":"14","author":"B Guan","year":"2020","unstructured":"Guan B, Li X, Xue W et al (2020) Blood lipid profiles and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Clin Lipidol 14:133-142.e3. https:\/\/doi.org\/10.1016\/j.jacl.2019.12.002","journal-title":"J Clin Lipidol"},{"key":"7827_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001211","volume":"3","author":"A Alonso","year":"2014","unstructured":"Alonso A, Yin X, Roetker NS et al (2014) Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the Framingham heart study. J Am Heart Assoc 3:e001211. https:\/\/doi.org\/10.1161\/JAHA.114.001211","journal-title":"J Am Heart Assoc"},{"key":"7827_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004067","volume":"19","author":"D Sagris","year":"2022","unstructured":"Sagris D, Harrison SL, Lip GYH (2022) Lipids and atrial fibrillation: new insights into a paradox. PLoS Med 19:e1004067. https:\/\/doi.org\/10.1371\/journal.pmed.1004067","journal-title":"PLoS Med"},{"key":"7827_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.arr.2014.12.001","volume":"19","author":"H-H Liu","year":"2015","unstructured":"Liu H-H, Li J-J (2015) Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev 19:43\u201352. https:\/\/doi.org\/10.1016\/j.arr.2014.12.001","journal-title":"Ageing Res Rev"},{"key":"7827_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004044","volume":"19","author":"M Ding","year":"2022","unstructured":"Ding M, Wennberg A, Gigante B et al (2022) Lipid levels in midlife and risk of atrial fibrillation over 3 decades-experience from the swedish AMORIS cohort: a cohort study. PLoS Med 19:e1004044. https:\/\/doi.org\/10.1371\/journal.pmed.1004044","journal-title":"PLoS Med"},{"key":"7827_CR40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","volume":"12","author":"Y-F Hu","year":"2015","unstructured":"Hu Y-F, Chen Y-J, Lin Y-J, Chen S-A (2015) Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 12:230\u2013243. https:\/\/doi.org\/10.1038\/nrcardio.2015.2","journal-title":"Nat Rev Cardiol"},{"key":"7827_CR41","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/STROKEAHA.115.012004","volume":"47","author":"H Kamel","year":"2016","unstructured":"Kamel H, Okin PM, Elkind MSV, Iadecola C (2016) Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 47:895\u2013900. https:\/\/doi.org\/10.1161\/STROKEAHA.115.012004","journal-title":"Stroke"},{"key":"7827_CR42","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1212\/WNL.0000000000000265","volume":"82","author":"LA Sposato","year":"2014","unstructured":"Sposato LA, Riccio PM, Hachinski V (2014) Poststroke atrial fibrillation: cause or consequence?: critical review of current views. Neurology 82:1180\u20131186. https:\/\/doi.org\/10.1212\/WNL.0000000000000265","journal-title":"Neurology"},{"key":"7827_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","volume":"16","author":"LAB Joosten","year":"2020","unstructured":"Joosten LAB, Cri\u015fan TO, Bjornstad P, Johnson RJ (2020) Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol 16:75\u201386. https:\/\/doi.org\/10.1038\/s41584-019-0334-3","journal-title":"Nat Rev Rheumatol"},{"key":"7827_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.numecd.2022.09.027","volume":"33","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia Y, Xu Q et al (2023) Association between myeloperoxidase and the risks of ischemic stroke, heart failure, and atrial fibrillation: a Mendelian randomization study. Nutr Metab Cardiovasc Dis 33:210\u2013218. https:\/\/doi.org\/10.1016\/j.numecd.2022.09.027","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"7827_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","volume":"37","author":"TJ VanderWeele","year":"2016","unstructured":"VanderWeele TJ (2016) Mediation analysis: a practitioner\u2019s guide. Annu Rev Public Health 37:17\u201332. https:\/\/doi.org\/10.1146\/annurev-publhealth-032315-021402","journal-title":"Annu Rev Public Health"},{"key":"7827_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41065-022-00243-y","volume":"159","author":"Y-L Nian","year":"2022","unstructured":"Nian Y-L, You C-G (2022) Susceptibility genes of hyperuricemia and gout. Hereditas 159:30. https:\/\/doi.org\/10.1186\/s41065-022-00243-y","journal-title":"Hereditas"},{"key":"7827_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41401-021-00640-5","volume":"43","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Jiang Y, Chen Y et al (2022) CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin 43:121\u2013132. https:\/\/doi.org\/10.1038\/s41401-021-00640-5","journal-title":"Acta Pharmacol Sin"},{"key":"7827_CR48","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","volume":"83","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub R (2023) Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs 83:1501\u20131521. https:\/\/doi.org\/10.1007\/s40265-023-01944-y","journal-title":"Drugs"},{"key":"7827_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1152\/physrev.00025.2013","volume":"95","author":"SK Nigam","year":"2015","unstructured":"Nigam SK, Bush KT, Martovetsky G et al (2015) The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev 95:83\u2013123. https:\/\/doi.org\/10.1152\/physrev.00025.2013","journal-title":"Physiol Rev"},{"key":"7827_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3390\/biom10040576","volume":"10","author":"CP Mart\u00ednez-Reyes","year":"2020","unstructured":"Mart\u00ednez-Reyes CP, Manjarrez-Reyna AN, M\u00e9ndez-Garc\u00eda LA et al (2020) Uric acid has direct proinflammatory effects on human macrophages by increasing proinflammatory mediators and bacterial phagocytosis probably via URAT1. Biomolecules 10:576. https:\/\/doi.org\/10.3390\/biom10040576","journal-title":"Biomolecules"},{"key":"7827_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","volume":"119","author":"A Paasche","year":"2024","unstructured":"Paasche A, Wiedmann F, Kraft M et al (2024) Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol 119:93\u2013112. https:\/\/doi.org\/10.1007\/s00395-023-01022-0","journal-title":"Basic Res Cardiol"},{"key":"7827_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cells13050450","volume":"13","author":"H Yanai","year":"2024","unstructured":"Yanai H, Adachi H, Hakoshima M et al (2024) A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular disease. Cells 13:450. https:\/\/doi.org\/10.3390\/cells13050450","journal-title":"Cells"},{"key":"7827_CR53","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/antiox12030780","volume":"12","author":"N Jamshidi","year":"2023","unstructured":"Jamshidi N, Nigam KB, Nigam SK (2023) Loss of the kidney urate transporter, Urat1, leads to disrupted redox homeostasis in mice. Antioxidants Basel Switz 12:780. https:\/\/doi.org\/10.3390\/antiox12030780","journal-title":"Antioxidants Basel Switz"},{"key":"7827_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152279","volume":"63","author":"Y Qu","year":"2023","unstructured":"Qu Y, Yu Y, Pan J et al (2023) Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies. Semin Arthritis Rheum 63:152279. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152279","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07827-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07827-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07827-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:57Z","timestamp":1769763717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07827-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7827"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07827-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}